Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
Begré L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, Béguelin C, Rockstroh J, Günthard H, Calmy A, Cavassini M, Stoeckle M, Schmid P, Bernasconi E, Levrero M, Zoulim F, Wandeler G, Rauch A, Swiss HIV Cohort Study (SHCS). Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy. HIV Med 2023; 25:291-298.
10.10.2023
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
10.10.2023
HIV Med 2023; 25:291-298
Begré Lorin, Boyd Anders, Salazar-Vizcaya Luisa, Suter-Riniker Franziska, Béguelin Charles, Rockstroh J K, Günthard Huldyrich F, Calmy Alexandra, Cavassini Matthias, Stoeckle Marcel, Schmid Patrick, Bernasconi Enos, Levrero Massimo, Zoulim Fabien, Wandeler Gilles, Rauch Andri, Swiss HIV Cohort Study (SHCS)
Weiter
